Introduction to the launch time and current selling price of momelotinib

Momelotinib is an oral small molecule tyrosine kinase inhibitor used to treat myelofibrosis. It mainly targets the JAK1 and JAK2 signaling pathways. Although the drug has been approved in many countries and regions around the world, as of now, molotinib has not been officially launched in mainland China. Therefore, if domestic patients need to use molotinib, they can only purchase it through regular overseas channels, which will also have a certain impact on the patient's medication route and cost.

In overseas markets, the original research version of molotinib is mainly the American version of the drug in the U.S. market. The price of the American version of molotinib is relatively high, with the latest selling price being about more than 200,000 yuan per bottle, which is a large financial burden for many patients. Due to its higher price, some patients may seek out more affordable alternatives or generics to relieve financial stress.

It is worth noting that the generic version of midostaurin produced by Lucius Pharmaceuticals has been approved by the Lao Ministry of Health for marketing. Although midostaurin and molotinib are different drugs, in the field of the same type of tyrosine kinase inhibitors, the price advantage of the Laos version of generic drugs is obvious. For example, the price of the generic version of midostaurin produced by Lucius is about 2,000 yuan, and the specification is 100mg*30 tablets. Its pharmaceutical ingredients are basically the same as those of the original drug, which greatly reduces the cost of medication for patients.

Overall, molotinib has not yet entered the Chinese market, and domestic patients can only obtain it through overseas channels. Due to the higher prices of original drugs, some patients will consider overseas generic drugs. With the emergence of more generic drugs and the advancement of relevant approvals, the accessibility and price of molotinib may improve in the future, further benefiting more myelofibrosis patients.

Reference materials:https://en.wikipedia.org/wiki/Momelotinib